Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple MyelomaJesús F. San Miguel, Hermann Einsele, Nikoletta Lendvai et al.|New England Journal of Medicine|2023Cited by 719
Guidelines for the diagnosis and management of multiple myeloma 2011Jennifer M. Bird, Judith Behrens, Roger G. Owen et al.|British Journal of Haematology|2011Cited by 305
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working GroupPhilippe Moreau, Jean‐Luc Harousseau, Shaji Kumar et al.|The Lancet Oncology|2021Cited by 266
Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trialMark T. Drayson, Janet Dunn, Stella Bowcock et al.|The Lancet Oncology|2019Cited by 160
APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation statusJohn Quinn, Kwee Yong|Blood|2010Cited by 64